Investigational drug · Phase 3
Flonoltinib
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for MF, MF,PMF,PPV-MF,PET-MF, Polycythemia Vera (PV).
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
12
Any phase or sponsor naming "Flonoltinib"
First trial start
2024
May 6, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Flonoltinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- MF
- MF,PMF,PPV-MF,PET-MF
- Polycythemia Vera (PV)
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Flonoltinib" as an intervention, largest first.
- A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk MyelofibrosisPivotal-lookingRecruiting
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT07317700 · 105 participants (planned) · Start Feb 13, 2026 · Primary completion Dec 30, 2027
Drug: Flonoltinib 75mg; Ruxolitinib Phosphate · For: MF
Sites: Chengdu, China; Tianjin, China
- Flonoltinib Maleate Oral Regimens in Patients With MyelofibrosisPivotal-lookingNot yet recruiting
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT07750574 · 105 participants (planned) · Start Nov 2026 · Primary completion Nov 2028
Drug: Flonoltinib Maleate orally; Flonoltinib Maleate orally and 1 more · For: Myelofibrosis; Myelofibrosis Due to and Following Polycythemia Vera; Myelofibrosis Transformation in Essential Thrombocythemia and 9 more
- A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk MyelofibrosisActive, not recruiting
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT06457425 · 75 participants · Start May 6, 2024 · Primary completion Nov 26, 2025
Drug: Flonoltinib 50mg; Flonoltinib 100mg and 1 more · For: MF,PMF,PPV-MF,PET-MF
Sites: Chengdu, China; Tianjin, China
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT07443306 · 64 participants (planned) · Start Mar 18, 2026 · Primary completion Dec 30, 2027
Drug: Flonoltinib Maleate · For: MF
Sites: Chengdu, China; Tianjin, China
- Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia VeraRecruiting
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT07232290 · 60 participants (planned) · Start Sep 23, 2025 · Primary completion Jul 30, 2027
Drug: Flonoltinib 75mg; Flonoltinib 100mg and 2 more · For: Polycythemia Vera (PV)
Sites: Tianjin, China
- Clinical Study on Drug Interactions of Flonoltinib Maleate TabletsNot yet recruiting
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT07768111 · 40 participants (planned) · Start Oct 30, 2026 · Primary completion Dec 30, 2026
Drug: 75mg Flonoltinib; 100mg Flonoltinib · For: Drug Interaction Research
Sites: Hefei, China
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT06387966 · 40 participants · Start Mar 18, 2024 · Primary completion Aug 15, 2024
Drug: Flonoltinib Maleate Tablets; Flonoltinib Maleate Tablets placebo · For: Heathly Subjects
Sites: Chengdu, China
- Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With MyeloproliferativeCompleted
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT05153343 · 31 participants · Start Dec 27, 2021 · Primary completion Nov 29, 2023
Drug: flonoltinib 25mg; flonoltinib 100mg and 3 more · For: Myeloproliferative Neoplasm (MPN); Myelofibrosis,MF
Sites: Chengdu, China
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT07193576 · 24 participants · Start Aug 4, 2024 · Primary completion Sep 11, 2024
Drug: flunotinib · For: Heathly Subjects
Sites: Chengdu, China
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT05713279 · 13 participants · Start May 23, 2023 · Primary completion Dec 1, 2023
Drug: SOC · For: COVID-19
Sites: Chengdu, China
Newest research
PubMed records naming it or its code names, newest first.
- Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial.
Yang L, Tan K, Liang R, et al. · Ther Adv Hematol 2026
- Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms.
Hu M, Yang T, Yang L, et al. · Blood Cancer J 2024
- Study on tissue distribution, metabolite profiling, and excretion of [14C]-labeled flonoltinib maleate in rats.
Ma Z, Tang M, Chen L · J Pharm Biomed Anal 2024
- Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis.
Ipek Y, Kilic B, Gunay UB, et al. · Expert Opin Investig Drugs 2023
- UPLC-MS/MS method development and application to pharmacokinetic study in rats and dogs of Flonoltinib Maleat.
Ma Z, Tang M, Pu Q, et al. · J Chromatogr B Analyt Technol Biomed Life Sci 2023
- Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms.
Hu M, Yang T, Yang L, et al. · Blood Cancer J 2022
Also in development for MF
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.